By Julia Karow

Life Technologies last week denied all allegations in a lawsuit that former Visigen Biotechnologies CEO and co-founder Susan Hardin filed in October 2009 against Life Tech, its Invitrogen unit, and Visigen, alleging breach of contract, fraud, negligent representation, and breach of fiduciary duty regarding Invitrogen's 2008 acquisition of Visigen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: Uncovering variants associated with diabetes-related kidney disease, a sequencing study of hepatitis E viruses circulating in Cambodia, and more.

Among Sacks' books was "Awakenings," which was later made into an Academy Award-winning film.

The popularity of the #sciencemoviequote Twitter trend showcases scientists' eclectic movie tastes and knack for puns. 

The popular astrophysicist warned that apathy and even contempt for science in politics could lead to the end of informed democracy. 

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Sep
24
Sponsored by
Personalis

This online seminar will outline a targeted enrichment technology to improve next-generation sequencing assays for cancer research and clinical applications. 

Oct
07
Sponsored by
Personal Genome Diagnostics

This webinar will highlight the key considerations and applications of next-generation sequencing for managing non-small cell lung cancer patients using plasma-based approaches. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.